Monkeys developed tooth and jaw abscesses and two died of protozoal infections. Human subjects developed cervical, ovarian, pancreatic, gastric and thyroid cancers and breast cancer " was the most common adverse event that led to discontinuation" in trials. Adverse event?
Ten people were hospitalized with the skin infection cellulitis during trials and one died.
But the FDA approved Amgen's Prolia (denosumab) in 2010 to prevent fractures in women with osteoporosis, two months earlier than expected. Why?
Anticipating Prolia's approval, Thousand Oaks, CA-based Amgen deployed 1,000 reps across its "bone health, inflammation and hospital teams" to call on a "large number of physicians including specialists and primary care physicians who treat postmenopausal osteoporosis," reported Medical Marketing & Media. Follow the tote bags.
No one seemed to notice that the FDA clinical reviewer Adrienne Rothstein, MD had stated that Prolia denosumab "has the potential to affect multiple layers of the immune system" before its approval and that "three subjects required hospitalization for pneumonia after a single dose." This is a great new "treatment options"?
The bone drug market opened up for the drug industry 12 years ago when the hormone replacement drugs women were taking to prevent fractures were found to increase their risks of cancer and heart disease. Bisphosphonates like Fosamax and Boniva (the latter, advertised by actress Sally Field) were quickly substituted as a way for women to keep their bones strong and stay young looking. But soon they r evealed risks of their own. In addition to intractable pain, atrial fibrillation and causing (not preventing) atypical fractures, bisphosphonates were linked to jaw bone death (osteonecrosis) and esophageal cancer.
Thanks, Big Pharma
Soon Prolia began to appear no safer than the bisophosphonates though it belonged to a different class of drugs. A monoclonal antibody derived from genetically engineered Chinese hamster ovary cells, Prolia carries warnings like other "MoAbs" about opportunistic infections, anaphylaxis and worse.